{"_default": {}, "triggers": {"1": {"rule_id": "balance_critical", "rule_name": "Solde critique", "priority": 1, "timestamp": "2026-01-21T19:40:51.988733", "context": {"recent_changes": [], "monitor_decision": {"should_trigger": false, "reason": "no_changes"}, "last_run_date": null, "current_balance": 0, "cash_runway_days": 180}, "saved_at": "2026-01-21T19:40:51.988836"}, "2": {"rule_id": "new_critical_invoice", "rule_name": "Facture critique d\u00e9tect\u00e9e", "priority": 1, "timestamp": "2026-01-21T19:47:30.199369", "context": {"recent_changes": [{"severity": "critical", "type": "new_row", "details": {"invoice_id": "F-DEMO-20260121-194632", "client_id": "CLI-LABORATOIR", "client_name": "Laboratoires BioPharm SAS", "invoice_date": "2025-09-22", "due_date": "2025-11-18", "amount": 850000.0, "status": "overdue", "payment_date": null, "days_overdue": 92, "risk_level": "critical"}}], "monitor_decision": {"should_trigger": true, "reason": "critical_change_detected (1 changes)"}, "last_run_date": "2026-01-21T19:41:30.157179", "current_balance": 4545500, "cash_runway_days": 165}, "saved_at": "2026-01-21T19:47:30.200075"}}, "runs": {"1": {"run_id": "deff4ba8-2cc5-4523-8db6-93e74a716c9c", "timestamp": "2026-01-21T19:41:30.157179", "trigger_reason": "Solde critique", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 8250000, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-012", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-002", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 3 factures en retard", "expected_impact": 981000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-008"]}, {"id": "ACTION-003", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-012"]}], "dg_note": "# Note DAF - Point Tr\u00e9sorerie et Risques\n**Date**: [Date du jour]  \n**Objet**: Situation de tr\u00e9sorerie et points de vigilance\n\n## Situation actuelle\n\nLa position de tr\u00e9sorerie de Demo PME-ETI pr\u00e9sente un solde de 4,545,500\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Le niveau d'encours clients s'\u00e9l\u00e8ve \u00e0 8,250,000\u20ac, face \u00e0 des dettes fournisseurs ma\u00eetris\u00e9es de 278,000\u20ac.\n\n## Points de vigilance\n\n\u2022 Un risque critique et quatre risques \u00e9lev\u00e9s ont \u00e9t\u00e9 identifi\u00e9s, repr\u00e9sentant une exposition totale de 4,540,000\u20ac\n\n\u2022 Le principal point d'attention concerne le Groupe Pharmaceutique Nord avec un retard de paiement de 525,000\u20ac, class\u00e9 en risque critique\n\n\u2022 La structure du BFR montre un d\u00e9s\u00e9quilibre significatif entre encours clients (8,25M\u20ac) et fournisseurs (278K\u20ac), n\u00e9cessitant une surveillance accrue\n\n## Recommandations\n\nActions imm\u00e9diates \u00e0 mettre en \u0153uvre :\n\n1. Engagement urgent aupr\u00e8s du Groupe Pharmaceutique Nord :\n   - Contact direct sous 24h\n   - Obtention d'un engagement \u00e9crit de paiement sous 48h\n   - Escalade au niveau Direction si n\u00e9cessaire\n\n2. Activation du plan de relance :\n   - Lancement imm\u00e9diat d'une campagne cibl\u00e9e sur les 3 factures en retard identifi\u00e9es\n   - Suivi quotidien des actions de recouvrement\n\n3. Reporting :\n   - Mise en place d'un suivi quotidien des encaissements attendus\n   - Point hebdomadaire sur l'\u00e9volution des risques identifi\u00e9s\n\nLa situation de tr\u00e9sorerie reste saine mais n\u00e9cessite une vigilance accrue sur les d\u00e9lais de paiement clients pour s\u00e9curiser notre position.", "risk_explanations": {"RISK-005": "Le retard de paiement de 525 000\u20ac du Groupe Pharmaceutique Nord repr\u00e9sente un risque critique car il d\u00e9passe la dur\u00e9e standard de recouvrement de plus de 90 jours, signalant potentiellement des difficult\u00e9s financi\u00e8res chez ce client majeur. Bien que la tr\u00e9sorerie actuelle soit confortable \u00e0 4,5M\u20ac, le montant en retard \u00e9quivaut au seuil critique de l'entreprise (500k\u20ac), ce qui pourrait compromettre notre capacit\u00e9 \u00e0 faire face \u00e0 des impr\u00e9vus. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, avec possibilit\u00e9 d'escalade juridique si aucun \u00e9ch\u00e9ancier n'est \u00e9tabli sous 7 jours."}, "action_justification": "Cette priorisation est logique pour les raisons suivantes :\n\nP1 (Appel Groupe Pharma Nord) : Priorit\u00e9 maximale car c'est une action rapide (appel) avec un impact financier imm\u00e9diat (525K\u20ac) sous 48h. Le timing court et le montant significatif en font un \"quick win\" \u00e9vident.\n\nP2 (Campagne relance) : Bien que le montant soit plus \u00e9lev\u00e9 (981K\u20ac), cette action n\u00e9cessite plus de temps et d'efforts pour sa mise en \u0153uvre. Le retour sur investissement est moins imm\u00e9diat qu'en P1.\n\nP3 (R\u00e9gularisation fournisseur) : Le faible montant (45K\u20ac) et l'impact limit\u00e9 sur la tr\u00e9sorerie justifient sa position en derni\u00e8re priorit\u00e9, malgr\u00e9 l'importance de maintenir de bonnes relations fournisseurs."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 12, "actions_count": 3}}, "2": {"run_id": "3732c5f7-5039-48f9-9dc3-2ab556d4cc54", "timestamp": "2026-01-21T19:48:05.901943", "trigger_reason": "Facture critique d\u00e9tect\u00e9e", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 9100000.0, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000.0, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000.0, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000.0, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-012", "category": "client_payment", "severity": "high", "score": 78, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-DEMO-20260121-194632 en retard de 64 jours", "amount_at_risk": 850000.0, "due_date": "2025-11-18", "entity_id": "CLI-LABORATOIR", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 64, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-013", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000.0, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000.0, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000.0, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000.0, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000.0, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000.0, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000.0, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000.0, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000.0, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-002", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 4 factures en retard", "expected_impact": 1491000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-012", "RISK-008"]}, {"id": "ACTION-003", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-013"]}], "dg_note": "# Note de Synth\u00e8se : Situation Tr\u00e9sorerie et Risques\n**Date :** [Date du jour]  \n**Objet :** Point de situation tr\u00e9sorerie et risques associ\u00e9s  \n**\u00c0 l'attention de :** La Direction G\u00e9n\u00e9rale\n\n## Situation actuelle\n\nLa position de tr\u00e9sorerie de Demo PME-ETI pr\u00e9sente un solde de 4,545M\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Le niveau d'encours clients s'\u00e9l\u00e8ve \u00e0 9,1M\u20ac, contrastant avec un encours fournisseurs ma\u00eetris\u00e9 de 278K\u20ac.\n\n## Points de vigilance\n\n- **Exposition globale** : Le montant total \u00e0 risque atteint 5,39M\u20ac, soit plus que notre solde de tr\u00e9sorerie actuel\n- **Risques identifi\u00e9s** : \n  * 1 risque critique \n  * 5 risques \u00e9lev\u00e9s\n- **Situation critique** : Un retard de paiement majeur du Groupe Pharmaceutique Nord pour 525K\u20ac n\u00e9cessite une action imm\u00e9diate\n\n## Recommandations\n\n1. **Actions imm\u00e9diates**\n   * Intervention directe aupr\u00e8s du Groupe Pharmaceutique Nord pour s\u00e9curiser un engagement de paiement sous 48h\n   * Lancement d'une campagne de relance cibl\u00e9e sur 4 factures en retard identifi\u00e9es comme prioritaires\n\n2. **Suivi et contr\u00f4le**\n   * Mise en place d'un reporting quotidien sur l'avancement des relances\n   * Point hebdomadaire sur l'\u00e9volution des encours \u00e0 risque\n\nLa situation de tr\u00e9sorerie reste saine mais n\u00e9cessite une vigilance accrue compte tenu du niveau d'exposition aux risques. Une action rapide sur les retards de paiement identifi\u00e9s permettra de s\u00e9curiser notre position.\n\n---\n*Document pr\u00e9par\u00e9 par le service Finance*", "risk_explanations": {"RISK-005": "Le retard de paiement de 525,000\u20ac du Groupe Pharmaceutique Nord repr\u00e9sente un risque critique car il d\u00e9passe la dur\u00e9e standard de recouvrement de plus de 90 jours, ce qui augmente significativement le risque d'impay\u00e9. Bien que la tr\u00e9sorerie actuelle soit confortable (4.5M\u20ac), ce montant \u00e9quivaut au seuil critique de l'entreprise (500k\u20ac), ce qui pourrait compromettre notre capacit\u00e9 \u00e0 faire face \u00e0 d'autres impr\u00e9vus. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, potentiellement via une mise en demeure."}, "action_justification": "La priorisation propos\u00e9e est logique pour les raisons suivantes :\n\nP1 - L'appel au Groupe Pharmaceutique Nord est urgent car il repr\u00e9sente un montant significatif (525K\u20ac) avec un fort taux de succ\u00e8s potentiel via un engagement direct. L'action est rapide (appel) pour un impact important.\n\nP2 - La campagne de relance est en P2 malgr\u00e9 un montant plus \u00e9lev\u00e9 (1,491M\u20ac) car elle n\u00e9cessite plus de temps/ressources et concerne plusieurs clients. Le retour sur investissement est moins imm\u00e9diat qu'en P1.\n\nP3 - La r\u00e9gularisation fournisseur est moins prioritaire car le montant est faible (45K\u20ac) et le risque de cons\u00e9quences n\u00e9gatives \u00e0 court terme est limit\u00e9. Cette action peut \u00eatre trait\u00e9e apr\u00e8s la s\u00e9curisation des encaissements clients.\n\nCet ordre maximise le ratio impact/effort en privil\u00e9giant d'abord les actions rapides \u00e0 fort enjeu financier."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 13, "actions_count": 3}}}}